NCT00624260

Brief Summary

The risk of recurrence in stage III and IV of colorectal cancers (CRC) is high during the three years following the tumoral resection with curative aim. Therefore, a prolonged follow-up and an intense monitoring are recommended to detect these recurrences precociously. Nevertheless, current consensual morphological and biological examinations are not very contributory, of difficult interpretation and expensive. The metabolic imagery in tomoscintigraphy by emission of positron coupled with the scanner, called PET-TDM, allows to identify more specifically recurrences, analyzes the whole body, detects hepatic metastasis more precociously and give some benefice for early diagnosis of lymph nodes recurrence. The principle purpose of this study is to evaluate if the systematic follow-up per PET-TDM allows detecting more often recurrences accessible to a curative surgery. We make the hypothesis that the systematic practice of PET- tomodensitometry (TDM) during the follow-up of CRC allows to decrease non curative recurrences appearance during the 3 years follow-up after a curative surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
240

participants targeted

Target at P50-P75 for not_applicable colorectal-cancer

Timeline
Completed

Started Jun 2008

Longer than P75 for not_applicable colorectal-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 15, 2008

Completed
12 days until next milestone

First Posted

Study publicly available on registry

February 27, 2008

Completed
3 months until next milestone

Study Start

First participant enrolled

June 1, 2008

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

March 18, 2016

Status Verified

March 1, 2016

Enrollment Period

7 years

First QC Date

February 15, 2008

Last Update Submit

March 17, 2016

Conditions

Keywords

Colorectal cancerRecurrencePositron Emission TomographyColorectal Cancer with high risk of recurrence stage IIIColorectal Cancer with high risk of recurrence stage IVT4N0M0 operated in emergency( because of perforation)

Outcome Measures

Primary Outcomes (1)

  • Percentage of patients with a non removable recurrence

    at the end of the study

Secondary Outcomes (3)

  • Survival without non removable tumor

    At the end of the study

  • Overall survival

    At the end of the study

  • Cost of the strategy

    At the end of the study

Study Arms (2)

2

ACTIVE COMPARATOR

Usual follow up : Pet-TDM for current indication (high isolated markers or before a metastasis curative resection)

Other: PET-TDM for current indication

1

EXPERIMENTAL

Semi-annual systematic PET-TDM (M6, M12, M18, M24, M30 and M36 after initial surgery)

Other: semi-annual systematic PET-TDM

Interventions

semi-annual systematic PET-TDM

1

PET-TDM for current indication (high isolated markers or before a metastasis curative resection)

2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with a removed colorectal adenocarcinoma since less than 6 months, in total remission and for whom a monitoring is necessary to detect recurrences precociously.
  • Patients with a T4N0M0 tumour and operated in emergency (because of a tumoral perforation) can be included. (suppressed by amendment 1)
  • before criteria have been replaced by : Patients with colorectal adenocarcinoma which is histologically proved and classified stage II perforated, III or IV, totally removed, in total remission,
  • if no metastatic, removed surgery must have been done since less 6 months;
  • if metastatic, all metastasis would have been removed, the last surgery dating less 6 months.(amendment 1)
  • Casual extension check-up would have been realized before initial surgery or during a period of 6 months after surgery performed in emergency.
  • informed consent signed
  • Age ≥ 18 years
  • Patient in ability to undergone hepatic or pulmonary resection in case of recurrence during the follow-up (ECOG ≤ 2)
  • Willingness to control visits

You may not qualify if:

  • pregnant or breast feeding women, or with a reproductive potential and no practicing an effective method of contraception during the second part of ovarian cycle ( PET is realised during the first part of ovarian cycle)
  • Cancer stage I or II (except T4 operated in emergency) or IV without possibility to remove metastasis or R2 after surgery.
  • Performance status contraindicating a hepatic or pulmonary surgery in case of recurrence.
  • Patients likely to undergone chemotherapy, surgery or radiotherapy during 2 weeks before PET-TDM.
  • Other progressive tumoral affection known, or colorectal cancer in progression.
  • (Bad compliance to the study procedure.)(suppressed by amendment 1)
  • Not balanced diabetes. (added by amendment 1)
  • Patients included in others clinical trials of imagery.
  • Inability to provide informed consent signed.
  • No social assurance.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Henri Mondor

Créteil, 94000, France

Location

Related Publications (1)

  • Sobhani I, Itti E, Luciani A, Baumgaertner I, Layese R, Andre T, Ducreux M, Gornet JM, Goujon G, Aparicio T, Taieb J, Bachet JB, Hemery F, Retbi A, Mons M, Flicoteaux R, Rhein B, Baron S, Cherrak I, Rufat P, Le Corvoisier P, de'Angelis N, Natella PA, Maoulida H, Tournigand C, Durand Zaleski I, Bastuji-Garin S. Colorectal cancer (CRC) monitoring by 6-monthly 18FDG-PET/CT: an open-label multicentre randomised trial. Ann Oncol. 2018 Apr 1;29(4):931-937. doi: 10.1093/annonc/mdy031.

MeSH Terms

Conditions

Colorectal NeoplasmsRecurrence

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Iradj Sobhani, MD, PhD

    Assistance Publique - Hôpitaux de Paris

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 15, 2008

First Posted

February 27, 2008

Study Start

June 1, 2008

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

March 18, 2016

Record last verified: 2016-03

Locations